This is the first time a nasally administered antibody has been given to a patient with SPMS Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said it has begun treating a patient with secondary progressive multiple sclerosis using nasally-administered Foralumab, the company’s fully-human anti-CD3 monoclonal antibody. The drug will be provided under the Food & Drug Administration’s individual patient expanded access protocol overseen by researchers at the Brigham and Women's Hospital (BWH), Harvard. This is the first time a nasally administered antibody has been given to a patient with SPMS. Sufferers of multiple sclerosis have limited treatment options with Tysabri, sold by Biogen Inc (NASDAQ:BIIB), one of the few drugs offering relief.